Bioperfectus Launched NEW RUO Product to Confront SARS-CoV-2 Delta Variant

Company news
2021-07-27

With surging cases of prevailing SARS-CoV-2Deltavariant, the testing of the variant has become a necessary and important measure to curb the further spread of the virus.

 

Source: GISAID, 2021,https://www.gisaid.org/hcov19-variants/

 

Under such circumstance, Bioperfectus, as a pioneer in the global molecular diagnostic market, is glad to launch our molecular RUO product to assist the detection of the SARS-CoV-2 variants.

 

Bioperfectus SARS-CoV-2 Variant B.1.617 Real Time PCR Kit is designed to detect L452R, E484Q, and P681R mutations in Sgene of SARS-CoV-2 and help to identify B.1.617.2 for research purpose.

Source: American Society for Microbiology, July 23, 2021,https://asm.org/Articles/2021/July/How-Dangerous-is-the-Delta-Variant-B-1-617-2

 

Our R&D team is closely tracking the reported SARS-CoV-2 variants worldwide and design assays for detecting emerging mutations related to increased infectiousness, immune escape, vaccine efficacy, and therapeutic medicines. Assays for these emerging mutation targets of interest will be available upon request.

 

Learn more : https://www.bioperfectus.com/productinfo/668939.html

Inquiry email : info@bioperfectus.com,marketing_global@bioperfectus.com

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14